An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

Conditions

• Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• ALXN2220 — DRUG
  To be administered as an IV infusion

Study Details

The purpose of Study ALXN2220-ATTRCM-302 is to evaluate the long-term safety, tolerability and efficacy of ALXN2220 in adult participants with ATTR-CM treated with ALXN2220 in addition to SoC who have completed Study ALXN2220-ATTRCM-301.

Key Dates

First listed

Aug 27, 2026

Start date

Nov 23, 2027

Status verified

Aug 2026

Primary completion

Jul 11, 2030

Completion

Jul 11, 2030

Study Design

Enrollment

1,180 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: ALXN2220
  Eligible participants will receive ALXN2220 administered IV q4w for a minimum of 12 months and up to 24 months or until participant has access to commercially available ALXN2220 for ATTR-CM, whichever occurs first.

Primary Outcome Measure

Percentage of participants with TEAEs [ Time Frame: Up to 24 months ]

Central Contacts

• Alexion Pharmaceuticals, Inc., Sponsor
  1-855-752-2356
  [email protected]

Locations (35)